Composition for inducing proliferation or accumulation of regulatory T cells

Patent metadata

Field	Value
Publication number	US-9433652-B2
Application number	US-201414492850-A
Country	US
Kind code	B2
Filing date	Sep 22, 2014
Priority date	Jun 4, 2010
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

First claim

The invention claimed is:

1. A method of treating a human subject having an infectious disease, an autoimmune disease, or an allergic disease, the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa to the human subject, wherein the bacterial strains are spore-forming bacteria and are isolated from a human.

2. The method of claim 1 , wherein the human subject has an infectious disease.

3. The method of claim 1 , wherein the human subject has an allergic disease.

4. The method of claim 1 , wherein the at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa comprise two or more strains belonging to Clostridium cluster IV.

5. The method of claim 1 , wherein the at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa comprise two or more strains belonging to Clostridium cluster XIVa.

6. The method of claim 1 , wherein the at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa comprise one or more strains belonging to Clostridium cluster IV and one or more strains belonging to Clostridium cluster XIVa.

7. The method of claim 1 , wherein the bacteria are isolated from a chloroform-treated human fecal sample.

8. The method of claim 1 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient.

9. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

10. The method of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the intestine.

11. The method of claim 10 , wherein the pharmaceutical composition comprises a pH sensitive composition comprising one or more enteric polymers.

12. The method of claim 10 , wherein the pharmaceutical composition is in the form of a capsule.

13. The method of claim 1 , wherein the bacteria are in the form of spores.

Assignees

• Univ Tokyo

Inventors

• Honda Kenya
• Atarashi Koji
• Itoh Kikuji
• Tanoue Takeshi

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/02

  Immunomodulators · CPC title